LL-37 Truncated Variants (KR-12 / KS-30) + GHRH (Growth Hormone-Releasing Hormone) stack
A research-context overview of stacking LL-37 Truncated Variants (KR-12 / KS-30) with GHRH (Growth Hormone-Releasing Hormone): the rationale, complementary benefits, side-effect overlap, and pharmacokinetic considerations. Educational only — never a recommendation.
Why this stack?
Pairing a Performance peptide like GHRH (Growth Hormone-Releasing Hormone) with a Recovery peptide like LL-37 Truncated Variants (KR-12 / KS-30) is one of the most common stack archetypes in the research literature. The Performance compound drives the GH/IGF-1 axis or anabolic signaling; the Recovery compound shortens the soft-tissue and inflammation tax of training, letting the anabolic signal land on healthier tissue. The two work on independent pathways, so timing concerns are minimal — most researchers dose them on separate clocks.
LL-37 Truncated Variants (KR-12 / KS-30)
Shorter active fragments of LL-37 (KR-12, KS-30) with retained antimicrobial activity but lower toxicity.
Key benefits
- ✓Antimicrobial activity preserved
- ✓Lower hemolysis vs full LL-37
- ✓Wound healing research
Side effects to watch
- ⚠Localized irritation (topical)
- ⚠Limited human trial data
GHRH (Growth Hormone-Releasing Hormone)
Native 44-aa hypothalamic GHRH; parent molecule of sermorelin, CJC-1295, and tesamorelin.
Key benefits
- ✓Pulsatile GH release
- ✓Preserves natural HPA axis
- ✓Reference comparator for analogs
Side effects to watch
- ⚠Flushing
- ⚠Headache
- ⚠Injection-site reactions
Half-life considerations
Reference half-life data for one or both of these compounds is not in our table — see the individual peptide profiles for cited PK ranges.
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.